) -- Shares of

Mead Johnson


surged on Tuesday on news that samples of its Enfamil formula involved in an U.S. Food and Drug Administration investigation did not contain a harmful bacteria to infants.

The FDA's investigation started after the death of a

10-day-old Missouri newborn

who consumed formula from a 12.5 ounce Enfamil can.

The infant's body tested positive for Cronobacter, which is a microorganism that plays a part in some rare but serious infant illnesses. The latest test results confirm Mead Johnson's own testing on the batch of formula before it was sold to the public. The FDA's probe is also looking into the water used to prepare the formula and other environmental factors, according to a Mead Johnson spokesman.

"Based on both sets of tests, Mead Johnson can say with confidence that Enfamil Premium Newborn formula, like every infant formula the company produces, is safe," the company said in a press release issued on Dec. 25. "All Mead Johnson infant formulas undergo more than 2,300 quality tests and checks to ensure that they meet or exceed all standards set by regulatory bodies, including the World Health Organization and the U.S. FDA."


formula brand was pulled last week



(WMT) - Get Report









(KR) - Get Report




Mead Johnson shares jumped 4.2% to $68.02 in morning action on volume of 3.5 million.

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here:

Alexandra Zendrian

>To submit a news tip, send an email to:


>To follow the writer on Twitter, go to

Alexandra Zendrian